Trial Profile
Phase 1 study of apatinib [YN-968D1] a inhibitor of angiogenesis
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 27 Feb 2017
Price :
$35
*
At a glance
- Drugs Rivoceranib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Apr 2008 New trial record.